Aida Pharmaceuticals, Inc. (AIDA)
Aida Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hangzhou, ZH, CN. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $8,101. On trailing twelve-month figures it carries a trailing P/E of 0.00, a net margin of 9.4%. Its beta of 3.84 implies it has historically moved more than the broad market.
Aida Pharmaceuticals, Inc., together with its affiliates, operates extensively throughout mainland China, specializing in the entire spectrum of pharmaceutical and genetic product development. This encompasses formulation, clinical trials, regulatory registration, manufacturing, sales, and marketing. The company's diverse product range includes antibiotics, cardiovascular medicines, and anti-cancer drugs. These are available in various forms, such as injectable powders, intravenous liquids, capsules, tablets, and ointments. Notable products feature Etimicin Sulfate, provided as an injectable powder, and rh-Apo2l, a biopharmaceutical therapy targeting cancers. Established in 1999, Aida Pharmaceuticals, Inc. is headquartered in Hangzhou, China.
Aida Pharmaceuticals, Inc. is most often compared with the following Healthcare names: